Moleculin Biotech (MBRX) Projected to Post Quarterly Earnings on Friday

Moleculin Biotech (NASDAQ:MBRX) is expected to issue its Q3 2025 results before the market opens on Friday, November 14th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, November 19, 2025 at 4:00 PM ET.

Moleculin Biotech (NASDAQ:MBRX) last announced its earnings results on Tuesday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, analysts expect Moleculin Biotech to post $-8 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Moleculin Biotech Stock Up 1.8%

Shares of NASDAQ:MBRX opened at $0.49 on Thursday. The business has a fifty day simple moving average of $0.46 and a 200-day simple moving average of $0.61. Moleculin Biotech has a 52 week low of $0.25 and a 52 week high of $3.65. The company has a market cap of $24.14 million, a P/E ratio of -0.15 and a beta of 1.57.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Wall Street Zen downgraded Moleculin Biotech to a “strong sell” rating in a report on Friday, October 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Wednesday, October 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Moleculin Biotech in a research note on Wednesday, September 10th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $4.00.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.